Difference between revisions of "Doxepine-maprotiline"

From Psychiatrienet
Jump to: navigation, search
 
Line 3: Line 3:
 
| to = maprotiline
 
| to = maprotiline
 
| stop =  
 
| stop =  
* Gradually reduce dosage of doxepin to a maximum of 50 mg/day.
+
{{downDoxepin}}
* When a dosage of 50 mg/day is reached, stop administration.
 
 
| start =  
 
| start =  
 
* No wash-out period is needed.  
 
* No wash-out period is needed.  
* Start administration of maprotiline the next day in a normal dosage of 25-75 mg/day.
+
* ''' Day 9: ''' start administration of maprotiline in a normal dosage of 25-75 mg/day.
|info =
 
{{review}}
 
 
 
 
}}
 
}}

Latest revision as of 14:37, 2 November 2015

Doxepin
Type antidepressant
Group TCA
links
ATC-code N06AA12
Medscape Doxepin
PubChem 3158
PubMed Doxepin
Drugs.com doxepin
Kompas (Dutch) Doxepin
Wikipedia Doxepin
Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline

Switch medication from doxepin to maprotiline.

Nietinrijdenbord.png Stop doxepin
  • Before day 1: gradually reduce dosage of doxepin to a maximum of 100 mg/day.
  • Day 1: reduce dosage of doxepin to 50 mg/day.
  • Day 3: reduce dosage of doxepin to 25 mg/day.
  • Day 8: stop administration of doxepin.
Eenrichtingbord.png Start maprotiline
  • No wash-out period is needed.
  • Day 9: start administration of maprotiline in a normal dosage of 25-75 mg/day.


  1. 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2015; Monografie "doxepine" (Dutch)
  2. NVZA; Toxicology.org; Monografie 63 (dutch)
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.